Marshall Wace’s Alder Biopharmaceuticals ALDR Stock Holding History

Marshall Wace’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-237,566	Closed	-$4.48M	–	2287
2019 Q3	$4.48M	Sell	237,566 -1,438,238	-86%	-$16.4M	0.04%	536
2019 Q2	$19.7M	Buy	1,675,804 +1,654,624	+7,812%	+$20M	0.16%	129
2019 Q1	$289K	Buy	+21,180	New	+$274K	﹤0.01%	1268
2017 Q1	–	Sell	-57,421	Closed	-$1.2M	–	896
2016 Q4	$1.2M	Sell	57,421 -468,721	-89%	-$12.2M	0.01%	732
2016 Q3	$17.2M	Sell	526,142 -418,317	-44%	-$12.7M	0.12%	185
2016 Q2	$23.6M	Buy	944,459 +769,439	+440%	+$20.8M	0.2%	129
2016 Q1	$4.29M	Buy	+175,020	New	+$4.05M	0.04%	380
2015 Q4	–	Sell	-108,105	Closed	-$3.54M	–	1197
2015 Q3	$3.54M	Buy	+108,105	New	+$4.6M	0.04%	351

Marshall Wace's ALDR Position: Q4 2019 in Review

Marshall Wace sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 237,566 shares — an estimated $4.48M sold.

Marshall Wace first reported a position in ALDR in Q3 2015 and held it in 8 quarters. The position peaked at $23.6M in Q2 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Marshall Wace reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Marshall Wace sold 237,566 Alder Biopharmaceuticals shares in Q4 2019, an estimated $4.48M.
Marshall Wace first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 8 quarters.
Marshall Wace's Alder Biopharmaceuticals position peaked at $23.6M in Q2 2016.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Marshall Wace's 13F filing for Q4 2019, filed 14 Feb 2020.